CompoundIQ

Disclaimer

CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.

OtherIntermediateHigh Risk

Cardarine

Also known as: GW-501516, Endurobol

Cardarine is not actually a SARM but a PPARδ agonist, often grouped with SARMs commercially. It was developed by GlaxoSmithKline for metabolic and cardiovascular diseases but was abandoned due to cancer findings in rodent studies.

Evidence52/100 — Moderate

Risk Level

High Risk

Difficulty

Intermediate
CAS Number317318-70-0
Molecular FormulaC21H18F3NO3S2
ClassOther
CategorySARMs

Mechanism of Action

GW-501516 activates PPARδ receptors, which regulate fatty acid oxidation and energy expenditure. It shifts the body's fuel preference from glucose to fat, dramatically increasing endurance capacity. It also improves lipid profiles by increasing HDL and decreasing LDL.

Dosing Research

Clinical trials used 2.5-10 mg/day. Research community references 10-20 mg/day. Half-life approximately 16-24 hours. Cycles typically 8-12 weeks.

Side Effects & Risks

Cancer development in rodent studies at high doses over extended periods led to drug abandonment. The relevance to humans at lower doses is debated. Limited long-term human safety data.

Research Studies

Disclaimer

CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.

Send Feedback

Help us improve CompoundIQ